Literature DB >> 23103620

Population pharmacokinetics of lamotrigine in Chinese children with epilepsy.

Da-ke He1, Li Wang, Jiong Qin, Shen Zhang, Wei Lu, Ling Li, Jian-ming Zhang, Wei-qun Bao, Xiao-qing Song, Hai-tao Liu.   

Abstract

AIM: To establish a population pharmacokinetics (PPK) model for lamotrigine (LTG) in Chinese children with epilepsy in order to formulate an individualized dosage guideline.
METHODS: LTG steady-state plasma concentration data from therapeutic drug monitoring (TDM) were collected retrospectively from 284 patients, with a total of 404 plasma drug concentrations. LTG concentrations were determined using a HPLC method. The patients were divided into 2 groups: PPK model group (n=116) and PPK valid group (n=168). A PPK model of LTG was established with NONMEM based on the data from PPK model group according to a one-compartment model with first order absorption and elimination. To validate the basic and final model, the plasma drug concentrations of the patients in PPK model group and PPK valid group were predicted by the two models.
RESULTS: The final regression model for LTG was as follows: CL (L/h)=1.01*(TBW/27.87)(0.635)*e(-0.753*VPA)*e(0.868*CBZ)*e(0.633*PB), Vd (L)= 16.7*(TBW/27.87). The final PPK model was demonstrated to be stable and effective in the prediction of serum LTG concentrations by an internal and external approach validation.
CONCLUSION: A PPK model of LTG in Chinese children with epilepsy was successfully established with NONMEM. LTG concentrations can be predicted accurately by this model. The model may be very useful for establishing initial LTG dosage guidelines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23103620      PMCID: PMC4011358          DOI: 10.1038/aps.2012.118

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  32 in total

1.  Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children.

Authors:  C Chen
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

2.  Effect of antiepileptic drug comedication on lamotrigine clearance.

Authors:  David Weintraub; Richard Buchsbaum; Stanley R Resor; Lawrence J Hirsch
Journal:  Arch Neurol       Date:  2005-09

3.  The concentration-effect relationship with lamotrigine (LTG)

Authors:  B E Gidal; T E Welty
Journal:  Epilepsia       Date:  1997-02       Impact factor: 5.864

4.  Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data.

Authors:  Z Hussein; J Posner
Journal:  Br J Clin Pharmacol       Date:  1997-05       Impact factor: 4.335

5.  Adding valproate to lamotrigine: a study of their pharmacokinetic interaction.

Authors:  A M Kanner; M Frey
Journal:  Neurology       Date:  2000-08-22       Impact factor: 9.910

Review 6.  Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy.

Authors:  Victor Biton
Journal:  Expert Opin Drug Metab Toxicol       Date:  2006-12       Impact factor: 4.481

7.  Population pharmacokinetics of lamotrigine in patients with epilepsy.

Authors:  J R Milovanovic; S M Jankovic
Journal:  Int J Clin Pharmacol Ther       Date:  2009-12       Impact factor: 1.366

8.  Bidirectional interaction of valproate and lamotrigine in healthy subjects.

Authors:  G D Anderson; M K Yau; B E Gidal; S J Harris; R H Levy; A A Lai; K B Wolf; W A Wargin; A T Dren
Journal:  Clin Pharmacol Ther       Date:  1996-08       Impact factor: 6.875

9.  Clinical experience with lamotrigine monotherapy in adults with newly diagnosed epilepsy: a review of published randomised clinical trials.

Authors:  E L Mullens
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 10.  Lamotrigine clinical pharmacokinetics.

Authors:  B Rambeck; P Wolf
Journal:  Clin Pharmacokinet       Date:  1993-12       Impact factor: 6.447

View more
  9 in total

1.  Authors' Reply to Standing et al.: "Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials".

Authors:  Sven C van Dijkman; Nico C B de Jager; Willem M Rauwé; Meindert Danhof; Oscar Della Pasqua
Journal:  Clin Pharmacokinet       Date:  2018-11       Impact factor: 6.447

2.  Pharmacometrics: a quantitative tool of pharmacological research.

Authors:  Qing-shan Zheng; Lu-jin Li
Journal:  Acta Pharmacol Sin       Date:  2012-11       Impact factor: 6.150

3.  Population pharmacokinetic models of lamotrigine in different age groups of Chinese children with epilepsy.

Authors:  Zhong-Bin Zhang; Shuang-Min Ji; Ying Han; Li-Li Zang; Ying-Hui Wang; Wei Lu; Li Wang; Ye Wu
Journal:  Eur J Clin Pharmacol       Date:  2017-01-07       Impact factor: 2.953

4.  Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials.

Authors:  Sven C van Dijkman; Nico C B de Jager; Willem M Rauwé; Meindert Danhof; Oscar Della Pasqua
Journal:  Clin Pharmacokinet       Date:  2018-08       Impact factor: 6.447

5.  Pharmacokinetic interactions and dosing rationale for antiepileptic drugs in adults and children.

Authors:  Sven C van Dijkman; Willem M Rauwé; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2017-11-07       Impact factor: 4.335

6.  Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters.

Authors:  Daniela Milosheska; Bogdan Lorber; Tomaž Vovk; Matej Kastelic; Vita Dolžan; Iztok Grabnar
Journal:  Br J Clin Pharmacol       Date:  2016-05-29       Impact factor: 4.335

Review 7.  Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update.

Authors:  Domenico Italiano; Emilio Perucca
Journal:  Clin Pharmacokinet       Date:  2013-08       Impact factor: 6.447

8.  Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling.

Authors:  Shansen Xu; Limin Liu; Yanan Chen; Mei Liu; Tong Lu; Huanxin Wang; Shihao Liu; Mingming Zhao; Limei Zhao
Journal:  Eur J Clin Pharmacol       Date:  2018-01-16       Impact factor: 2.953

9.  Effects of Comedication and Genetic Factors on the Population Pharmacokinetics of Lamotrigine: A Prospective Analysis in Chinese Patients With Epilepsy.

Authors:  Zhan-Zhang Wang; Yue-Feng Zhang; Wen-Can Huang; Xi-Pei Wang; Xiao-Jiao Ni; Hao-Yang Lu; Jin-Qing Hu; Shu-Hua Deng; Xiu-Qing Zhu; Huan-Shan Xie; Hong-Zhen Chen; Ming Zhang; Chang Qiu; Yu-Guan Wen; De-Wei Shang
Journal:  Front Pharmacol       Date:  2019-07-25       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.